2024-514744-91-00RecruitingPhase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATX304
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 12 Jun 2024
- Start date
- 3 Aug 2026
- Lead sponsor
- Betagenon AB
- Diseases
- Obesity
- EU CT number
- 2024-514744-91-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 64
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.